Dupilumab (Dupixent®) for moderate-to-severe atopic dermatitis in adolescent patients. HTA ID: 19056

Assessment Status Rapid review complete
HTA ID 19056
Drug Dupilumab
Brand Dupixent®
Indication For the treatment of moderate-to-severe atopic dermatitis in adolescents 12 years and older who are candidates for systemic therapy.
Assessment Process
Rapid review commissioned 17/12/2019
Rapid review completed 17/01/2019
Rapid review outcome A HTA is not recommended. The NCPE recommends that dupilumab not be considered for reimbursement at the submitted price*

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013

The HSE has approved reimbursement following confidential price negotiations April 2021.